| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a methionine derivative, H-Met-OtBu·HCl does not have a specific biological target. Its primary utility is as a chemical building block in peptide synthesis. However, methionine itself is an essential amino acid that plays important roles in protein synthesis, methylation reactions, and sulfur metabolism. In its protected ester form, the compound is primarily used as a synthetic intermediate rather than as a bioactive molecule. It can be hydrolyzed to release methionine, which is a precursor for S-adenosylmethionine, cysteine, and glutathione, but the protected form is not designed for biological activity.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
H-Met-OtBu·HCl does not exhibit pharmacological activity in vitro. As a protected amino acid ester, it is a synthetic intermediate rather than a bioactive compound. In vitro studies using this compound focus on its chemical reactivity, such as its use in peptide bond formation reactions or its stability under various conditions. The compound may be used as a substrate in enzymatic assays to study esterase activity, as the tert-butyl ester can be cleaved by certain hydrolases. However, these are analytical or preparative applications rather than assessments of pharmacological activity. The compound does not bind to receptors, inhibit enzymes, or produce cytotoxic effects in cell-based assays. |
| ln Vivo |
H-Met-OtBu·HCl is not a pharmacologically active compound and therefore does not have defined in vivo activity as a drug. When administered to animals, the compound would likely be hydrolyzed by esterases to release methionine, which would then enter normal metabolic pathways. The tert-butyl ester may provide enhanced lipophilicity compared to free methionine, potentially improving membrane permeability and oral absorption. However, the compound is not used therapeutically, and its in vivo effects would be limited to those of the released methionine, which is an essential amino acid. Its primary value remains in synthetic chemistry.
|
| Enzyme Assay |
In vitro enzyme assays for H-Met-OtBu·HCl are typically designed to study esterase or protease activity. A standard protocol involves incubating the compound with an enzyme preparation in a suitable buffer at physiological pH. The hydrolysis of the tert-butyl ester releases methionine and tert-butanol, which can be quantified by HPLC, GC, or mass spectrometry. Alternatively, the decrease in substrate concentration can be monitored. These assays are used to characterize the substrate specificity of esterases, to screen for enzyme inhibitors, or to evaluate the stability of tert-butyl ester protecting groups in biological matrices.
|
| Cell Assay |
In vitro cellular assays using H-Met-OtBu·HCl are limited due to the compound's role as a synthetic intermediate rather than a bioactive molecule. However, it can be used in cell culture studies to investigate the intracellular delivery of methionine via ester hydrolysis. Cells are cultured in media supplemented with the compound, and cellular uptake, ester hydrolysis, and methionine release are monitored. The effects of increased intracellular methionine on cellular metabolism, protein synthesis, or glutathione production can be assessed. The compound's ability to penetrate cell membranes may be enhanced by the lipophilic tert-butyl ester group.
|
| Animal Protocol |
In vivo animal studies with H-Met-OtBu·HCl are primarily conducted in the context of nutritional or metabolic research. A typical protocol involves oral or intraperitoneal administration of the compound to rodents. Blood samples are collected at various time points to measure methionine and tert-butanol levels, allowing assessment of the compound's absorption, hydrolysis, and pharmacokinetics. The compound's ability to elevate plasma methionine concentrations and its effects on methionine metabolism, transsulfuration, or methylation pathways may be evaluated.
|
| ADME/Pharmacokinetics |
As a methionine tert-butyl ester, H-Met-OtBu·HCl is expected to be absorbed after oral administration. The compound is likely hydrolyzed by esterases to release methionine and tert-butanol. The tert-butyl ester may enhance lipophilicity and membrane permeability compared to free methionine, potentially improving oral bioavailability. Following hydrolysis, methionine enters the endogenous amino acid pool and is distributed throughout the body. Methionine is metabolized through various pathways, including transmethylation, transsulfuration, and remethylation.
|
| Toxicity/Toxicokinetics |
The hydrochloride salt of methionine tert-butyl ester is generally considered to have low toxicity, consistent with its use as a chemical reagent and its metabolic conversion to the essential amino acid methionine. The compound is not classified as a carcinogen, mutagen, or reproductive toxicant. Standard laboratory safety precautions, including the use of personal protective equipment, are recommended. No significant systemic toxicity is anticipated at typical research doses.
|
| References | |
| Additional Infomation |
4-Iodo-L-phenylalanine is the L-enantiomer of 4-iodophenylalanine and also the enantiomer of 4-iodo-D-phenylalanine.
L-Methionine tert-butyl ester hydrochloride (H-Met-OtBu·HCl, CAS 24250-85-9) is a protected amino acid derivative used as a building block in peptide synthesis. Its chemical formula is C₉H₂₀ClNO₂S and molecular weight is 241.78. The compound appears as a solid. The tert-butyl ester provides acid-labile protection for the carboxyl group. It is intended for research use only. |
| Molecular Formula |
C9H10INO2
|
|---|---|
| Molecular Weight |
291.0857
|
| Exact Mass |
290.975
|
| CAS # |
24250-85-9
|
| PubChem CID |
134497
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
366.8±32.0 °C at 760 mmHg
|
| Flash Point |
175.6±25.1 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.653
|
| LogP |
2.14
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
179
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
IC1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])[C@@]([H])(C(=O)O[H])N([H])[H]
|
| InChi Key |
PZNQZSRPDOEBMS-QMMMGPOBSA-N
|
| InChi Code |
InChI=1S/C9H10INO2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)/t8-/m0/s1
|
| Chemical Name |
(2S)-2-amino-3-(4-iodophenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~20 mg/mL (~68.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4354 mL | 17.1768 mL | 34.3536 mL | |
| 5 mM | 0.6871 mL | 3.4354 mL | 6.8707 mL | |
| 10 mM | 0.3435 mL | 1.7177 mL | 3.4354 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
